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Abstract 
Background: Irisin is a hormone released mainly from skeletal muscle after exercise which increases adipose tissue 
energy expenditure. Adipocytes can also release irisin after exercise, acting as a local adipokine to induce white adi-
pose tissue to take on a brown adipose tissue-like phenotype, suggesting that irisin and its receptor may represent a 
novel molecular target for the treatment of obesity and obesity-related diabetes. Previous reports provide conflicting 
evidence regarding circulating irisin levels in patients with type 2 diabetes (T2DM).
Methods: This study investigated plasma irisin concentrations in 79 T2DM individuals, assessing potential associa-
tions with measures of segmental body composition, markers of endothelial dysfunction and peripheral blood mono-
nuclear cell telomere length (TL).
Results: Resting, overnight-fasted plasma irisin levels were significantly higher in this group of T2DM patients com-
pared with levels we previously reported in healthy volunteers (p < 0.001). Moreover, plasma irisin displayed a positive 
correlation with body mass index (p = 0.04), body fat percentage (p = 0.03), HbA1c (p = 0.03) and soluble E-selectin 
(p < 0.001). A significant negative association was observed between plasma irisin and visceral adiposity (p = 0.006) 
in T2DM patients. Multiple regression analysis revealed that circulating soluble E-selectin levels could be predicted by 
plasma irisin (p = 0.004). Additionally, cultured human umbilical vein endothelial cells (HUVEC) exposed to 200 ng/
ml irisin for 4 h showed a significant fourfold increase in E-selectin and 2.5-fold increase in ICAM-1 gene expression 
(p = 0.001 and p = 0.015 respectively), and there was a 1.8-fold increase in soluble E-selectin in conditioned media 
(p < 0.05).
Conclusion: These data suggest that elevated plasma irisin in T2DM is associated with indices of adiposity, and that 
irisin may be involved in pro-atherogenic endothelial disturbances that accompany obesity and T2DM. Accordingly, 
irisin may constitute a potentially novel therapeutic opportunity in the field of obesity and cardiovascular diabetology.
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Introduction
Irisin is a recently identified hormone derived from the 
fibronectin type III domain-containing (FNDC5) gene 
that is released mainly from skeletal muscle after exercise 
or exposure to cold [1–3]. The ability of irisin, via yet 
undetermined receptors, to reprogram white adipose 
tissue (WAT) cells to take on the phenotype of brown 
adipose tissue (BAT) has been proposed as a potential 
therapeutic target for metabolic disorders, including 
obesity and type 2 diabetes (T2DM) [4–7]. Indeed, expo-
sure to irisin leads to suppressed expression of several 
genes characteristic to WAT, whilst there is a concomi-
tant increase in uncoupled respiration via induction of 
uncoupling protein-1 (UCP1) expression and altered 
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expression of other established BAT genes [8–10]. Thus 
irisin can promote energy expenditure via thermogenesis 
[11]. Release of irisin has also been described from adi-
pose tissue, suggesting that this hormone is an adipokine, 
as well as a myokine [12, 13]. Irisin release from WAT, 
as from muscle, is stimulated by exercise and reduced in 
fasted animals [12]. To date, there is conflicting evidence 
regarding possible association(s) between circulating 
irisin and body mass index (BMI): some data indicate a 
positive correlation [14], whilst other studies have found 
either no association [15] or a negative association [16]. 
Moreover, the role of irisin in T2DM remains unclear. 
Initial studies reported decreased circulating irisin lev-
els in T2DM patients compared to healthy individuals 
[17, 18], whereas studies performed in obese individuals 
(some of whom had T2DM) have reported elevated levels 
[14, 19]. Recent data indicate that irisin may be involved 
in cardiovascular physiology, with evidence emerging 
that it plays a role in atherosclerosis [20–22] and can 
predict cardiovascular disease (CVD) risk [23, 24] This 
highlights the potential significance of irisin as a bio-
marker in T2DM patients who are at an increased CVD 
risk [25]. Moreover, we previously reported that plasma 
irisin levels can predict TL, a marker of biological ageing 
in healthy non-obese individuals, suggesting that irisin 
may provide a marker of ageing, as well as energy balance 
[26]. Since irisin is emerging as a new factor implicated 
in the pathophysiology of obesity and a potential oppor-
tunity to treat obesity, further appreciation of the role of 
irisin in obesity-related diabetes is required, particularly 
in relation to factors implicated in endothelial dysfunc-
tion and atherosclerosis, such as E-selectin.
E-selectin is a key adhesion molecule which along-
side other endothelial adhesion molecules, serves to 
anchor leukocytes to the endothelium in inflammation 
and elevated soluble E-selectin levels have been identi-
fied in hypertension, diabetes and hyperlipidemia [27]. 
E-selectin is not constitutively expressed by endothelial 
cells [28], but is known to be expressed and released from 
activated endothelium both in vitro [29] and in vivo [30]. 
E-selectin expression is stimulated by exposure to inflam-
matory molecules including tumour necrosis factor-
alpha (TNF-α) and interleukin-1 (IL-1) [31].
The present study investigated plasma irisin lev-
els in a cohort of T2DM patients, examining associa-
tions between plasma irisin, indices of adiposity, ageing 
and circulating markers of endothelial dysfunction. The 
effects of exposure of primary cultured human endothe-
lial cells to high irisin levels on expression and secre-
tion of soluble forms of adhesion molecules was also 
investigated.
Materials and methods
Study participants
A group of 79 individuals with T2DM (42 males, 37 
females; mean BMI 31.5 ± 5.4 kg/m2) was recruited from 
the diabetes outpatient clinics at the Heart of England 
NHS Foundation Trust, Birmingham, UK. The study 
exclusion criteria included pregnancy, recent hospitali-
zation, other significant disease (e.g. cancer or immune 
disorders), and other significant treatments (e.g. oral cor-
ticosteroids). All subjects were asked to fast overnight for 
a minimum of 8 h and to refrain from exercise for at least 
12 h prior to study sampling. The study was approved by 
the Aston University Research Ethics Committee and 
the Staffordshire NHS Research Ethics Committee and 
written informed consent was given by all participants 
according to the principles of the Declaration of Helsinki.
Anthropometric and biochemical measures
Segmental body composition was measured using bio-
electrical impedance analysis (BIA) (BC-601 Bioimped-
ance Analyser  Tanita®). Analyses included segmental 
fat mass (FM), fat free mass (FFM) and a calculated 
visceral fat score (calculated by the manufacturer’s soft-
ware; a score of 1–12 is considered healthy; 13–59 indi-
cates excess visceral fat) in all subjects. Abdominal fat 
and fat free muscle readings are subtracted from other 
segmental readings to estimate the body trunk. Body 
weight was measured to the nearest 0.1  kg and height 
to the nearest 1  cm, whilst BMI was determined as 
body weight in kilograms divided by the square of the 
height in metres (kg/m2). A fasting sample of venous 
whole blood was collected into  K+-EDTA coated tubes 
(Vacutainer, Becton–Dickinson, UK). Plasma was sepa-
rated by cooled centrifugation (1300g for 10  min) and 
samples were stored at − 80  °C until analysed. For tel-
omere length analysis, genomic DNA extraction was 
performed on whole blood aliquots using the  QIAamp® 
DNA blood mini kit (Qiagen, UK). DNA was resus-
pended in elution buffer (10  mM Tris·Cl; 0.5  mM 
EDTA; pH 9.0). Isolated DNA was quantified using the 
NanoDrop-1000 (NanoDrop Technologies, USA) and 
diluted in pure water to a concentration of 5 ng/µl and 
stored at − 80 °C.
Fasting whole blood glucose was measured using an 
Accucheck Advantage blood glucose meter. Glycated 
haemoglobin (HbA1c) was measured by mass spectrom-
etry. Plasma irisin (Phoenix Peptides, Germany), leptin, 
soluble E-selectin, soluble thrombomodulin, C-reactive 
protein (CRP) (R&D Systems, UK) and insulin (Merco-
dia, Sweden) concentrations were all assessed by ELISA 
following protocols provided by the manufacturers. The 
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homeostatic model assessment (HOMA) method was 
used to assess β-cell function (HOMA-β), and insulin 
resistance (HOMA-IR) was used to derive insulin sensi-
tivity (HOMA-S) as previously described [32], according 
to the following equations:
Relative telomere length analysis was measured using 
an established real-time polymerase chain reaction (RT-
PCR) to produce a relative expression ratio of telomeric 
DNA to genomic DNA control (T/S ratio) [26, 33].
Cell culture and gene expression analysis
Early passage primary human umbilical vein endothe-
lial cells (HUVECs) (Caltag Medsystems, UK) were 
grown in supplemented proprietary human large ves-
sel endothelial cell basal medium (Caltag Medsystems, 
UK) in a 37 °C, 5%  CO2 humidified incubator. Cells were 
seeded at 1  ×  105 cells per well in a 12-well plate and 
allowed to attach for 48  h before exposure to 0, 20 and 
200  ng/ml recombinant human irisin (Caymen Chemi-
cals, USA) for 4 or 24  h. Total RNA was isolated using 
EZNA RNA Isolation kit (VWR, UK), and treated with 
DNase (Promega, UK) to remove any traces of genomic 
material. RNA quantification was performed using 
the Nanodrop 1000 (Thermofisher). Samples (500  ng) 
of total RNA were reverse transcribed using Preci-
sion nanoscript™ reverse transcriptase (Primerdesign, 
Southampton UK) and oligo dT primers (PrimerDe-
sign, Southampton, UK). cDNAs were amplified using 
a Stratagene MX3000P thermal cycler in a standard 
40-cycle  SYBR® green real-time PCR reaction followed 
by a melt curve analysis to assess amplicon specificity. 
Gene expression was assessed with the following prim-
ers, E-selectin (sense AGAGGTTCCTTCCTGCCAAG, 
antisense CAGAGCCATTGAGGGTCCAT), P-selec-
tin (sense CGCCTGCCTCCAGACCATCTTC, anti-
sense CTATTCACATTCCAGAAACTCACCACAGC), 
ICAM1 (sense GACTCCAATGTGCCAGGCTT, anti-
sense TAGGTGCCCTCAAGATCTCG) and PECAM1 
(sense ATTGCAGTGGTTATCATCGGAGTG, antisense 
CTCGTTGTTGGAGTTCAGAAGTGG) were assessed. 
Data were normalised to expression of the housekeep-
ing genes actin and YWHAZ (pre-validated primers pur-
chased from Primerdesign, UK) and analysed for fold 
changes in gene expression using the comparative CT 
method with statistical analysis determined using the 
HOMA-β% = [20× fasting insulin (mIU/l)]/
Glucose(mmol/l)− 3.5
HOMA-IR = [Glucose (mmol/l)
× fasting insulin (mIU/l)]/22.5
HOMA-S = 1/HOMA-IR
freely available Relative Expression Software Tool (REST 
2009, http://www.qiagen.com).
HUVEC ELISA for soluble E‑selectin
The concentration of soluble E-selectin in cell super-
natants derived from HUVEC cells treated with 20 and 
200 ng/ml irisin for a period of 4 and 24 h was quantified 
using soluble E-selectin ELISA (R&D Systems, UK) as per 
manufacturer’s instructions.
Statistical analysis
Results are presented as mean  ±  standard deviation 
(SD), unless otherwise stated. Comparisons between 
cohorts and analysis of E-selectin expression data were 
performed using unpaired t tests. For analysis within 
the cohort of T2DM individuals, associations between 
plasma irisin and other circulating factors with anthro-
pometric measures were explored individually using 
Pearson’s bivariate correlations. Natural log-transformed 
telomere length was assessed to ensure that associa-
tions with T/S ratio always remained non-negative, 
ensuring that the decline in telomere length with age 
followed a biologically consistent negative exponential 
decay model. Subsequently, linear regression was used 
to investigate whether plasma irisin levels were signifi-
cantly predictive of plasma soluble E-selectin levels. For 
all analyses a p value of < 0.05 was considered to be sta-
tistically significant.
Results
Body anthropometry and biochemical analyses of T2DM 
patients
Table  1 presents the results of the anthropometric and 
biochemical analyses in the T2DM study cohort. Over-
all, the T2DM patients exhibited measurements indica-
tive of central obesity, including an average BMI > 30 kg/
m2 with high average body fat and abdominal (trunk) fat 
percentages (34.9 and 34.1%, respectively) and an aver-
age visceral fat score above the healthy range (>  13). 
Biochemical analyses showed an expected elevation of 
fasting blood glucose (9.9  mmol/l), with concomitantly 
elevated levels of pro-inflammatory factors, including 
leptin (1530  ng/ml), C-reactive protein (4.5  μg/ml) and 
soluble E-selectin (50.9  ng/ml). In the T2DM cohort 
overnight-fasted, resting, plasma irisin levels were sig-
nificantly higher than levels previously noted in healthy 
volunteers (175.4  ±  131  ng/ml vs. 46.7  ±  32.4  ng/ml; 
p < 0.0001).
Associations of plasma irisin with biochemical 
and anthropometric factors in type 2 diabetes
Pearson’s bivariate correlations between plasma irisin 
and anthropometric and biochemical measures and T/S 
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ratio were assessed and associations are represented in 
Table 2. BMI (p = 0.04), total fat percentage (p = 0.033), 
HbA1c (p = 0.032) and E-selectin (p < 0.0001) exhibited 
significant positive associations with plasma irisin lev-
els in the T2DM cohort. Visceral fat score (p =  0.006) 
displayed a significant negative association with plasma 
irisin levels, as did age (p =  0.001) and circulating lep-
tin (p =  0.02). No other factors measured in this study 
displayed any significant associations with plasma irisin 
in T2DM subjects, including T/S ratio which, as previ-
ously shown, is predicted by plasma irisin in healthy 
individuals [33]. Figure 1 shows the scatterplots of these 
associations.
Plasma irisin predicts E‑selectin levels in type 2 diabetes
Multivariate regression analysis was used to test the most 
significant associations with soluble E-selectin. In the 
T2DM cohort, plasma irisin was significantly predictive 
for soluble E-selectin, with a β value of 0.382 and an  r2 
value of 24.7 (p = 0.004).
E‑selectin and ICAM‑1 gene expression is induced 
in HUVECs by exposure to high but not low irisin levels
To investigate the biological mechanism underlying the 
association between irisin and E-selectin, HUVEC cells 
were treated for 4 or 24 h with low (20 ng/ml) and high 
(200  ng/ml) recombinant human irisin. SYBR  Green® 
Real-time PCR analysis of E-selectin and ICAM-1 gene 
expression showed that exposure to high irisin induced 
a fourfold and 2.5-fold increase in mRNA expression 
respectively compared to control (Fig.  2b, p  <  0.05). 
Exposure to low irisin caused no significant difference in 
E-selectin expression levels (Fig. 2a, p > 0.05). No other 
markers of endothelial inflammation tested, i.e. P-selec-
tin, and platelet endothelial cell adhesion molecule-1 
(PECAM-1), were altered by exposure to irisin. Expres-
sion of E-selectin after 24 h of treatment was returned to 
basal levels (Fig. 2c, d).
Soluble E‑selectin concentration is increased in culture 
supernatant obtained from HUVECs exposed to high irisin 
concentrations for 4 h and returns to baseline after 24 h
As measured by ELISA, culture supernatants from 
HUVECs treated for 4  h with 200  ng/ml recombinant 
Table 1 Anthropometric and  biochemical measurements 
in individuals with type 2 diabetes (T2DM)
Homeostatic model assessment for beta cell function (HOMA-β) and insulin 
sensitivity (HOMA-S). Data are presented as mean ± S.D. for normal continuous 
variables
Anthropometric and biochemical analysis  Type 2 diabetes cohort
Cohort size 79
Men 42
Women 37
Age (years) 56 ± 12
Height (cm) 165 ± 10
Weight (kg) 87 ± 20.5
Body mass index (kg/m2) 31.5 ± 5.4
Total fat (%) 34.9 ± 9.3
Total muscle (kg) 53 ± 11.8
Abdominal (trunk) fat (%) 34.1 ± 9.4
Abdominal (trunk) muscle (kg) 29 ± 5.7
Visceral fat score (0–60) 13.2 ± 5.5
Fasting blood glucose (mmol/l) 9.9 ± 3.8
HbA1c (mmol/mol) 70.5 ± 17.6
Fasting insulin (mU/l) 29.1 ± 42.6
HOMA β (%) 67.2 ± 67.9
HOMA-S 74 ± 71
Telomere length (T/S ratio) 1.6 ± 0.2
Irisin (ng/ml) 175.4 ± 131
Leptin (pg/ml) 1529 ± 1372
Thrombomodulin (ng/ml) 6.6 ± 6.3
E-selectin (ng/ml) 50.9 ± 21.4
C-reactive protein (µg/ml) 4.5 ± 3.99
Table 2 Results of Pearson’s bivariate correlations analysis
Pearson’s bivariate correlations between anthropometric/biochemical 
parameters and fasting plasma irisin levels. Homeostatic model assessment 
for beta cell function (HOMA β) and insulin sensitivity (HOMA-S). Data are 
represented as positive or negative correlation coefficients with p values < 0.05 
indicating statistical significance (in italic text)
Measurement β value p value
Age − 0.364 0.001
Height − 0.171 0.13
Weight 0.089 0.43
Body mass index (kg/m2) 0.223 0.04
Total fat (%) 0.241 0.03
Total muscle (kg) − 0.134 0.23
Abdominal (trunk) fat (%) 0.062 0.59
Abdominal (trunk) muscle (kg) − 0.173 0.13
Visceral fat score − 0.3 0.006
Fasting blood glucose (mmol/l) − 0.03 0.79
HbA1c (mmol/mol) 0.28 0.03
Fasting insulin (mU/l) 0.08 0.46
HOMA β (%) 0.01 0.92
HOMA-S 0.05 0.65
Leptin (pg/ml) − 0.24 0.02
Thrombomodulin (ng/ml) − 0.16 0.15
E-selectin (ng/ml) 0.43 < 0.0001
C-reactive protein (µg/ml) 0.05 0.62
T/S ratio − 0.11 0.3
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human irisin had 1.8-fold increased soluble E-selec-
tin concentration compared to HUVECs treated with 
20 ng/ml of irisin for 4 h (Fig. 3, p < 0.05). Incubation for 
24  h with 200  ng/ml irisin resulted in soluble E-selectin 
concentrations similar to the levels detected in the control 
group treated with regular growth media. HUVECs treated 
with TNF-α produced the highest levels of soluble E-selec-
tin (Fig. 3, p ≤ 0.0001) and were used as a positive control.
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Fig. 1 Associations between plasma irisin levels and anthropometric/biochemical measures. In our study cohort of type 2 diabetic patients, 
Pearson’s correlation tests showed significant positive associations between plasma irisin and body mass index (BMI) (a p = 0.04); total fat (%) (b 
p = 0.03); HbA1c (c p = 0.032) and E-selectin (e p < 0.001); and a significant negative association between plasma irisin levels and the visceral fat 
score (d p = 0.006)
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Discussion
The current study provides evidence that circulat-
ing irisin levels are increased in fasted obese T2DM 
patients compared with levels which we have previously 
established for healthy non-diabetic controls [33]. The 
increased circulating irisin in T2DM showed a significant 
positive association with plasma soluble E-selectin. The 
anthropometric analyses in the present study revealed 
a high BMI with high total and abdominal body fat per-
centage within the T2DM cohort, whereas the muscle 
mass of these patients did not differ significantly from 
values previously reported for a non-diabetic cohort 
[33]. As irisin is a myokine, this raises the possibility that 
the increased irisin levels in the T2DM patients may be 
entering the circulation from a tissue source other than 
muscle. The strong association between plasma irisin 
and measures of obesity (including percentage truncal 
fat), suggest that circulating irisin in this study cohort 
may be determined by the degree of adiposity. The pre-
sent results are consistent with previously published data 
showing correlations between body fat and circulating 
irisin levels [14, 23, 34].
Although the elevation of circulating irisin in obese 
T2DM may constitute a compensatory response to 
decreased energy expenditure, possibly due to lack of 
exercise or innate defects in metabolism [20, 23] it is 
also plausible that excess adipose tissue in these patients 
could provide an extra source of irisin. This is consistent 
with recent studies in obese subjects showing that plasma 
irisin decreased markedly in response to a hypocaloric 
diet and weight loss, together with significant reductions 
in hyperglycaemia and hyperinsulinaemia [35–37].
It should be also noted that the measurement of irisin 
in biological samples via immunological methodologies 
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Fig. 2 Exposure to recombinant human irisin induces E-selectin and ICAM-1 gene expression in primary HUVECs. Real-time PCR analysis of 
irisin-treated HUVEC, displaying intracellular adhesion molecule 1 (ICAM1), platelet endothelial cell adhesion molecule (PECAM1), P-selectin and 
E-selectin mRNA expression levels. a Exposure to 20 ng/ml irisin for 4 h caused no changes in gene expression relative to control. b Exposure to 
200 ng/ml irisin for 4 h induced a fourfold increase in E-selectin and 2.5-fold increase in ICAM-1 mRNA expression compared to control (p = 0.001 
and p = 0.014 respectively). c Exposure to 20 ng/ml irisin for 24 h caused no significant alteration in expression of genes associated with endothe-
lial dysfunction relative to control and neither did, d exposure to 200 ng/ml for 24 h. Values normalised to actin and YWHAZ expression (n = 4). 
**p<0.01, ***p<0.001 and ****p<0.0001
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is not without controversy. Indeed, there is some dis-
parity in the reported levels of irisin in serum or plasma 
depending on the methodology used in detecting it [38]. 
As such, there is currently no universally accepted ‘ref-
erence range’ or normal value for circulating irisin in 
healthy individuals and some even question its existence 
[39]. Although it has been suggested that a ‘normal’ cir-
culating concentration of irisin may fall in the narrow 
range of 3.6–4.6 ng/ml [40], plasma irisin levels similar to 
those observed in the present study have been indepen-
dently reported previously [41, 42]. Moreover, the ELISA 
used in the present study has been previously tested 
against both Western blotting [43] and mass spectrom-
etry [44].
Irisin and T2DM
The presently observed plasma irisin concentrations in 
obese T2DM are interestingly not consistent with pre-
vious studies showing lower levels of circulating irisin 
in T2DM compared to healthy subjects. However, the 
newly diagnosed T2DM patients in the previous study 
by Choi et al. were younger, and with a markedly lower 
BMI compared to the present subjects [45]. Thus, the 
differences in circulating irisin levels between the studies 
may be at least partly related to these phenotypic vari-
ables. Furthermore, whilst the cohort characteristics in 
the study by Liu et al. were closer to the present cohort, 
the higher mean BMI herein may account for the differ-
ences in irisin values [46]. The absence of muscle mass 
and body fat measures in these previous studies makes it 
difficult to assess the extent of adiposity in their subjects. 
Additionally, it is possible that differences of ethnicity, 
diet and parameters identified in the present study may 
have influenced the irisin levels. The importance of a 
link between adiposity and circulating irisin cannot be 
overlooked, particularly if obese individuals are exposed 
to chronically elevated plasma irisin levels which could 
potentially confer a state of ‘irisin resistance’. Youn et al, 
examined serum irisin levels in a cohort of 424 subjects, 
classifying them according to lower, middle and upper 
tertiles of skeletal muscle to visceral fat ratio (SVR). 
Serum irisin was correlated with favourable metabolic 
phenotypes in those subjects within the upper tertile. 
However, there were no such correlations in the lower 
tertile. The authors concluded that circulating irisin is 
dysfunctionally altered in subjects with lower skeletal 
muscle mass and higher visceral fat [47] which carries 
implications for any application of irisin as a potential 
anti-obesity treatment [5, 12].
Moreover, in the present study a strong positive cor-
relation was noted between HbA1c and plasma irisin 
levels, suggesting a relationship between circulating iri-
sin levels and glycaemic control. This is supported by 
previous research that indicated that plasma irisin is 
associated with elevated blood glucose concentrations 
[48], whilst evidence also exists that irisin can increase 
glucose uptake in skeletal muscle cells in  vitro in an 
AMPK-dependent manner [49]. Further work is required 
therefore to clarify the potential role of irisin in glucose 
homeostasis and metabolic disease.
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Fig. 3 The effect of recombinant human irisin on soluble E-selectin in primary HUVECs. HUVEC cells were treated for a 4 and b 24 h with recombi-
nant human irisin (20 and 200 ng/ml). TNF-α treatment (10 ng/ml) was used as a positive control (negative control treated only with regular growth 
media). Supernatant was collected and soluble E-selectin was measured by ELISA. Data was analysed using one way ANOVA with Tukeys multiple 
comparison test. Data are presented as mean ± SEM; statistical significance was set at p < 0.05. **p<0.01, ***p<0.001 and ****p<0.0001
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Irisin and soluble E‑selectin
In addition to the associations between anthropomet-
ric measures and plasma irisin levels, there was a strong 
positive association between irisin and soluble E-selectin 
levels. Multiple regression analysis showed that amongst 
the factors that exhibited a significant association with 
soluble E-selectin levels (Table  2), soluble E-selectin 
was the only factor to significantly predict plasma iri-
sin levels. This is an important finding since elevated 
soluble E-selectin levels are a key marker of endothe-
lial dysfunction in T2DM [50, 51], which accompanies 
diabetes-related micro- and macro-vascular complica-
tions [52–54]. To further explore this hypothesis, we uti-
lized HUVEC cells as a model of the endothelium and 
observed that exposure to irisin, at concentrations com-
parable to those in many of the obese T2DM patients 
of this study, induced a significant increase in E-selectin 
gene and protein expression (Figs. 2, 3). Since the concen-
tration of soluble E-selectin is directly proportional to its 
cell surface expression [55], this supports a potential role 
for irisin in increasing cell surface expression of E-selec-
tin. The precise physiological role of soluble E-selectin is 
yet to be fully elucidated, although studies have shown 
that E-selectin can exert a chemotactic signal towards 
neutrophils, and may trigger T cell migration. Existing 
literature has reported a positive relationship between 
soluble E-selectin and pro-inflammatory chemokines, 
oxidative stress, endothelial dysfunction and incidences 
of T2DM and CVD [56, 57]. Additionally, Tabak et  al. 
have previously reported a relationship between irisin 
and low-grade inflammation, a hallmark of metabolic 
syndrome [58]. Therefore, circulating soluble E-selectin 
levels are useful as a clinical tool to support a diagnosis 
of acute inflammatory processes and atherogenic risk 
[59]. The mechanism(s) of action of irisin in endothelial 
cell activation remains to be clarified, however the evi-
dence presented here suggests that irisin may provide a 
novel link between increased adiposity and endothelial 
dysfunction.
Conclusion
The benefits of exercise in obesity and diabetes are well 
known and the prospect of utilising newly discovered 
hormonal pathways that may mimic these effects is 
tantalising [60]. The discovery of irisin and its poten-
tial role in energy regulation provide a potential step 
in this direction. Since the initial discovery of irisin by 
Bostrom et  al. there have been several clinical stud-
ies investigating associations between circulating irisin 
and body composition and T2DM [61]. The results so 
far have been inconsistent, with the exact role of irisin 
in metabolic disorders yet to be fully elucidated possi-
bly relating to differences in study methodology, which 
either focus on either skeletal muscle or adipose tissue. 
The current study considers both tissue types, however 
the precise mechanisms by which irisin is regulated and 
released from both muscle and adipose tissue, and also 
the diverse effects of circulating irisin which impact 
nutrient homeostasis and endothelial function are yet to 
be elucidated.
Abbreviations
BMI: body mass index; BAT: brown adipose tissue; CVD: cardiovascular disease; 
CRP: C-reactive protein; FFM: fat free mass; FNDC5: fibronectin type III domain-
containing; HUVECs: human umbilical vein endothelial cells; IL-1: interleukin-1; 
ICAM1: intracellular adhesion molecule 1; PECAM-1: platelet endothelial 
cell adhesion molecule-1; RT-PCR: real-time polymerase chain reaction; FM: 
segmental fat mass; SVR: skeletal muscle to visceral fat ratio; TL: telomere 
length; HOMA: the homeostatic model assessment; TNF-α: tumour necrosis 
factor-alpha; T2DM: type 2 diabetes; UCP1: uncoupling protein-1; WAT: white 
adipose tissue.
Authors’ contributions
KSR, JEB made substantial contributions to the study conception, design and 
acquisition and analysis of data, and was involved in drafting and revising the 
manuscript. CP made substantial contributions to acquisition of data, or analy-
sis and interpretation of data and was involved in drafting and revising the 
manuscript. IA made substantial contributions to the analysis and interpreta-
tion of data and was involved in drafting and revising the manuscript. DN, CJB, 
HRG made substantial contributions to the study conception and design and 
was involved in drafting and revising the manuscript. EJH, SB made substantial 
contributions to the study conception and design and acquisition of data and 
was involved in drafting and revising the manuscript. IK, HSR made substantial 
contributions to the interpretation of data and was involved in drafting and 
revising the manuscript. All authors read and approved the final manuscript.
Author details
1 Aston Research Centre for Healthy Ageing and School of Life and Health 
Sciences, Aston University, Birmingham B4 7ET, UK. 2 Aston Medical Research 
Institute, Aston Medical School, Aston University, Birmingham B4 7ET, UK. 
3 Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabo-
lism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, 
Coventry CV2 2DX, UK. 4 Translational & Experimental Medicine, Division 
of Biomedical Sciences, Warwick Medical School, University of Warwick, 
Coventry CV4 7AL, UK. 5 Department of Diabetes and Endocrinology, Diabetes 
Outpatient Clinics at the Heart of England NHS Foundation Trust, Birming-
ham B9 5SS, UK. 6 Faculty of Health and Medical Sciences, University of Surrey, 
Guildford GU2 7XH, UK. 
Acknowledgements
The authors would like to acknowledge the support or research nurses at 
Heart of England NHS Foundation Trust and Professor Alan Nevill for guidance 
on statistical analysis.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The datasets generated and/or analysed during the current study are not pub-
licly available but anonymised data may be available from the corresponding 
author on reasonable request.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approved by the Aston University Research Ethics Committee 
(Reference Project 444) and the Staffordshire NHS Research Ethics Commit-
tee (Reference 11/WM/0288) and written informed consent was given by all 
participants according to the principles of the Declaration of Helsinki.
Page 9 of 10Rana et al. Cardiovasc Diabetol  (2017) 16:147 
Funding
The present study was cofounded by Aston University and Heart of England 
NHS Foundation Trust.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 19 September 2017   Accepted: 28 October 2017
References
 1. Cunha A. Basic research: irisin-behind the benefits of exercise. Nat Rev 
Endocrinol. 2012;8:195.
 2. Lee P, Linderman JD, Smith S, Brychta RJ, Wang J, Idelson C, Perron RM, 
Werner CD, Phan GQ, Kammula US, et al. Irisin and FGF21 are cold-
induced endocrine activators of brown fat function in humans. Cell 
Metab. 2014;19:302–9.
 3. Panati K, Suneetha Y, Narala VR. Irisin/FNDC5—an updated review. Eur 
Rev Med Pharmacol Sci. 2016;20:689–97.
 4. Hofmann T, Elbelt U, Stengel A. Irisin as a muscle-derived hormone stimu-
lating thermogenesis—a critical update. Peptides. 2014;54C:89–100.
 5. Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C, Garcia-Gimenez JL. 
Irisin: a new potential hormonal target for the treatment of obesity and 
type 2 diabetes. J Diabetes. 2012;4:196.
 6. Pyrzak B, Demkow U, Kucharska AM. Brown adipose tissue and browning 
agents: irisin and FGF21 in the development of obesity in children and 
adolescents. Adv Exp Med Biol. 2015;866:25–34.
 7. Leung PS. The potential of irisin as a therapeutic for diabetes. Future Med 
Chem. 2017;9:529–32.
 8. Mahajan RD, Patra SK. Irisin, a novel myokine responsible for exercise 
induced browning of white adipose tissue. Indian J Clin Biochem. 
2013;28:102–3.
 9. Huh JY, Dincer F, Mesfum E, Mantzoros CS. Irisin stimulates muscle 
growth-related genes and regulates adipocyte differentiation and 
metabolism in humans. Int J Obes. 2014;38:1538–44.
 10. Zhang Y, Xie C, Wang H, Foss RM, Clare M, George EV, Li S, Katz A, Cheng 
H, Ding Y, et al. Irisin exerts dual effects on browning and adipogenesis of 
human white adipocytes. Am J Physiol Endocrinol Metab. 2016;311:E530–41.
 11. Castillo-Quan JI. From white to brown fat through the PGC-1alpha-
dependent myokine irisin: implications for diabetes and obesity. Dis 
Model Mech. 2012;5:293–5.
 12. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones 
F, Ricart W, Fernandez-Real JM. Irisin is expressed and produced by 
human muscle and adipose tissue in association with obesity and insulin 
resistance. J Clin Endocrinol Metab. 2013;98:E769–78.
 13. Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Crujeiras AB, 
Seoane LM, Casanueva FF, Pardo M. FNDC5/irisin is not only a myokine 
but also an adipokine. PLoS ONE. 2013;8:e60563.
 14. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circu-
lating levels of irisin in patients with anorexia nervosa and different stages 
of obesity–correlation with body mass index. Peptides. 2013;39:125–30.
 15. Sanchis-Gomar F, Alis R, Pareja-Galeano H, Sola E, Victor VM, Rocha M, 
Hernandez-Mijares A, Romagnoli M. Circulating irisin levels are not 
correlated with BMI, age, and other biological parameters in obese and 
diabetic patients. Endocrine. 2014;46:674–7.
 16. Yuksel MA, Oncul M, Tuten A, Imamoglu M, Acikgoz AS, Kucur M, Madazli 
R. Maternal serum and fetal cord blood irisin levels in gestational diabetes 
mellitus. Diabetes Res Clin Pract. 2014;104:171–5.
 17. Liu JJ, Liu S, Wong MD, Tan CS, Tavintharan S, Sum CF, Lim SC. Relationship 
between circulating irisin, renal function and body composition in type 2 
diabetes. J Diabetes Complicat. 2014;28:208–13.
 18. Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, Srbecky 
M, Imrich R, Kyselovicova O, Belan V, et al. Effects of obesity, diabetes 
and exercise on Fndc5 gene expression and irisin release in human 
skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol. 
2014;592:1091–107.
 19. Rodrigues KF, Pietrani NT, Bosco AA, Ferreira CN, Gomes KB. Circulating 
irisin is increased in type 2 diabetes mellitus and correlates with fasting 
glucose levels. Apollo Med. 2016;13:152–5.
 20. Sesti G, Andreozzi F, Fiorentino TV, Mannino GC, Sciacqua A, Marini 
MA, Perticone F. High circulating irisin levels are associated with insulin 
resistance and vascular atherosclerosis in a cohort of nondiabetic adult 
subjects. Acta Diabetol. 2014;51:705–13.
 21. Zhang Y, Song H, Zhang Y, Wu F, Mu Q, Jiang M, Wang F, Zhang W, Li 
L, Shao L, et al. Irisin inhibits atherosclerosis by promoting endothelial 
proliferation through microRNA. J Am Heart Assoc. 2016;5:126–5.
 22. Zhang Y, Mu Q, Zhou Z, Song H, Zhang Y, Wu F, Jiang M, Wang F, Zhang 
W, Li L, et al. Protective effect of irisin on atherosclerosis via suppressing 
oxidized low density lipoprotein induced vascular inflammation and 
endothelial dysfunction. PLoS ONE. 2016;11:e0158038.
 23. Hee Park K, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, 
Tsoukas MA, Geladari EV, Huh JY, Dincer F, et al. Circulating irisin in rela-
tion to insulin resistance and the metabolic syndrome. J Clin Endocrinol 
Metab. 2013;98:4899–907.
 24. Efe TH, Acar B, Ertem AG, Yayla KG, Algul E, Yayla C, Unal S, Bilgin M, Cimen 
T, Kirbas O, Yeter E. Serum irisin level can predict the severity of coronary 
artery disease in patients with stable angina. Korean Circ J. 2017;47:44–9.
 25. Taylor KS, Heneghan CJ, Farmer AJ, Fuller AM, Adler AI, Aronson JK, 
Stevens RJ. All-cause and cardiovascular mortality in middle-aged people 
with type 2 diabetes compared with people without diabetes in a large 
U.K. primary care database. Diabetes Care. 2013;36:2366–71.
 26. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids 
Res. 2002;30:e47.
 27. Roldan V, Marin F, Lip GY, Blann AD. Soluble E-selectin in cardiovascular 
disease and its risk factors. A review of the literature. Thromb Haemost. 
2003;90:1007–20.
 28. Jubeli E, Moine L, Vergnaud-Gauduchon J, Barratt G. E-selectin as a 
target for drug delivery and molecular imaging. J Control Release. 
2012;158:194–206.
 29. Melrose J, Tsurushita N, Liu G, Berg EL. IFN-gamma inhibits activation-
induced expression of E- and P-selectin on endothelial cells. J Immunol. 
1998;161:2457–64.
 30. Fries JW, Williams AJ, Atkins RC, Newman W, Lipscomb MF, Collins T. 
Expression of VCAM-1 and E-selectin in an in vivo model of endothelial 
activation. Am J Pathol. 1993;143:725–37.
 31. Ley K. The role of selectins in inflammation and disease. Trends Mol Med. 
2003;9:263–8.
 32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and beta-cell function 
from fasting plasma glucose and insulin concentrations in man. Diabeto-
logia. 1985;28:412–9.
 33. Rana KS, Arif M, Hill EJ, Aldred S, Nagel DA, Nevill A, Randeva HS, Bailey CJ, 
Bellary S, Brown JE. Plasma irisin levels predict telomere length in healthy 
adults. Age. 2014;36:995–1001.
 34. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider 
BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulat-
ing concentrations in serum and plasma and II. mRNA expression and 
circulating concentrations in response to weight loss and exercise. 
Metabolism. 2012;61:1725–38.
 35. Crujeiras AB, Pardo M, Arturo RR, Santiago NC, Zulet MA, Martinez JA, 
Casanueva FF. Longitudinal variation of circulating irisin after an energy 
restriction-induced weight loss and following weight regain in obese 
men and women. Am J Hum Biol. 2014;26:198–207.
 36. de la Iglesia R, Lopez-Legarrea P, Crujeiras AB, Pardo M, Casanueva FF, 
Zulet MA, Martinez JA. Plasma irisin depletion under energy restriction 
is associated with improvements in lipid profile in metabolic syndrome 
patients. Clin Endocrinol. 2014;81(2):306–11.
 37. Crujeiras AB, Zulet MA, Lopez-Legarrea P, de la Iglesia R, Pardo M, Carreira 
MC, Martinez JA, Casanueva FF. Association between circulating irisin 
levels and the promotion of insulin resistance during the weight mainte-
nance period after a dietary weight-lowering program in obese patients. 
Metabolism. 2014;63:520–31.
 38. Kalayci M. Preanalytical, analytical, and postanalytical errors in the meas-
urement of irisin levels. Pol Arch Intern Med. 2017;127(9):643.
 39. Albrecht E, Norheim F, Thiede B, Holen T, Ohashi T, Schering L, Lee S, 
Brenmoehl J, Thomas S, Drevon CA, Erickson HP, Maak S. Irisin—a myth 
rather than an exercise-inducible myokine. Sci Rep. 2015;9(5):8889.
Page 10 of 10Rana et al. Cardiovasc Diabetol  (2017) 16:147 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 40. Jedrychowski MP, Wrann CD, Paulo JA, Gerber KK, Szpyt J, Robinson 
MM, Nair KS, Gygi SP, Spiegelman BM. Detection and quantitation of 
circulating human irisin by tandem mass spectrometry. Cell Metab. 
2015;22(4):734–40.
 41. Elizondo-Montemayor L, Silva-Platas C, Torres-Quintanilla A, Rodriguez-
Lopez C, Ruiz-Esparza GU, Reyes-Mendoza E, Garcia-Rivas G. Association 
of irisin plasma levels with anthropometric parameters in children with 
underweight, normal weight, overweight, and obesity. Biomed Res Int. 
2017;2017:2628968.
 42. Hew-Butler T, Landis-Piwowar K, Byrd G, Seimer M, Seigneurie N, Byrd B, 
Muzik O. Plasma irisin in runners and nonrunners: no favorable metabolic 
associations in humans. Physiol Rep. 2015;3(1):e12262.
 43. Wen MS, Wang CY, Lin SL, Hung KC. Decrease in irisin in patients with 
chronic kidney disease. PLoS ONE. 2013;8(5):e64025.
 44. Lee DC, Pate RR, Lavie CJ, Sui X, Church TS, Blair SN. Leisure-time running 
reduces all-cause and cardiovascular mortality risk. J Am Coll Cardiol. 
2014;64(5):472–81.
 45. Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, Kim JG, Lee IK, Park 
KG. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin 
Pract. 2013;100:96–101.
 46. Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, Tavintharan S, Sum CF, Lim 
SC. Lower circulating irisin is associated with type 2 diabetes mellitus. J 
Diabetes Complicat. 2013;27:365–9.
 47. Hwang Y-C, Jeon WS, Park C-Y, Youn B-S. The ratio of skeletal muscle 
mass to visceral fat area is a main determinant linking circulating irisin to 
metabolic phenotype. Cardiovasc Diabetol. 2016;15:9.
 48. Chang CL, Huang SY, Soong YK, Cheng PJ, Wang CJ, Liang IT. Circulating 
irisin and glucose-dependent insulinotropic peptide are associated with 
the development of polycystic ovary syndrome. J Clin Endocrinol Metab. 
2014;99:E2539–48.
 49. Lee HJ, Lee JO, Kim N, Kim JK, Kim HI, Lee YW, Kim SJ, Choi JI, Oh Y, Kim JH, 
et al. Irisin, a novel myokine, regulates glucose uptake in skeletal muscle 
cells via AMPK. Mol Endocrinol. 2015;29:873–81.
 50. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunc-
tion and risk of type 2 diabetes mellitus. JAMA. 2004;291:1978–86.
 51. Abu-Amero KK, Al-Mohanna F, Al-Boudari OM, Mohamed GH, Dzimiri 
N. The interactive role of type 2 diabetes mellitus and E-selectin S128R 
mutation on susceptibility to coronary heart disease. BMC Med Genet. 
2007;8:35.
 52. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. 
Endothelial dysfunction in diabetes: the role of reparatory mechanisms. 
Diabetes Care. 2011;34(Suppl 2):S285–90.
 53. Tian J, Wen Y, Yan L, Cheng H, Yang H, Wang J, Kozman H, Villarreal D, Liu 
K. Vascular endothelial dysfunction in patients with newly diagnosed 
type 2 diabetes and effects of 2-year and 5-year multifactorial interven-
tion. Echocardiography. 2011;28:1133–40.
 54. Hamilton SJ, Watts GF. Endothelial dysfunction in diabetes: pathogenesis, 
significance, and treatment. Rev Diabet Stud. 2013;10:133–56.
 55. Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme 
TM, Ahern TJ, Buurman WA. E-selectin and intercellular adhesion 
molecule-1 are released by activated human endothelial cells in vitro. 
Immunology. 1992;77:543–9.
 56. Chang TT, Chen JW. Emerging role of chemokine CC motif ligand 4 
related mechanisms in diabetes mellitus and cardiovascular disease: 
friends or foes? Cardiovasc Diabetol. 2016;15(1):117.
 57. Odegaard AO, Jacobs DR Jr, Sanchez OA, Goff DC Jr, Reiner AP, Gross MD. 
oxidative stress, inflammation, endothelial dysfunction and incidence of 
type 2 diabetes. Cardiovasc Diabetol. 2016;15:51.
 58. Tabak O, Simsek G, Erdenen F, Sozer V, Hasoglu T, Gelisgen R, Altunoglu E, 
Muderrisoglu C, Senyigit A, Uzun H. The relationship between circulating 
irisin, retinol binding protein-4, adiponectin and inflammatory mediators 
in patients with metabolic syndrome. Diabetologia. 2017;60(7):1252–60.
 59. Kulidjian AA, Issekutz AC, Issekutz TB. Differential role of E-selectin and 
P-selectin in T lymphocyte migration to cutaneous inflammatory reac-
tions induced by cytokines. Int Immunol. 2002;14:751–60.
 60. Teixeira-Lemos E, Nunes S, Teixeira F, Reis F. Regular physical exercise 
training assists in preventing type 2 diabetes development: focus on 
its antioxidant and anti-inflammatory properties. Cardiovasc Diabetol. 
2011;10:12.
 61. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, 
Boström EA, Choi JH, Long JZ, et al. A PGC1α-dependent myokine that 
drives browning of white fat and thermogenesis. Nature. 2012;481:463–8.
